Oncopeptides’ Pepaxto Needs New Study To Identify Population That Will Benefit, FDA Panel Says

 
• By Sue Sutter
Dim room
Pepaxto's near-term future in the US appears dim following a strongly negative advisory committee vote. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers